The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients

NCT05289986 | Terminated Phase 4

• 1 other identifier: CRF006
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 2

Brief Summary

This is an open label, randomised, two-arm switch study over 48 weeks in which virally suppressed participants on a stable combined ART regimen will be randomised (1:1) to an immediate switch to 3TC/TDF/DOR (immediate switch arm, N=30) for the duration of the 48-week study, or to maintaining their current cART followed by a switch to 3TC/TDF/DOR from week 24-48 (delayed switch arm, N=30). Participants will be monitored for the length of the study (48 weeks) plus a 30-day follow-up period. If patients withdraw or are withdrawn from the study treatment prematurely, an early termination visit (ETV) should occur within 30 days post withdrawal. The hypothesis of the study is that a switch to Delstrigo, which is a combination of tenofovir disoproxil, lamivudine and doravirine (TDF/3TC/DOR) has a favourable impact on lipid metabolism, glucose, weight, body composition and hepatic steatosis.

Conditions

Hiv

Outcome Measures

Primary Outcomes (1)

• To quantify the effect on lipid profile

  To quantify the effect on lipid profile (change from baseline in total fasting cholesterol to Week 24) of switching from suppressive, stable cART containing ABA/3TC or TAF/FTC plus dolutegravir or bictegravir to Delstrigo (TDF/3TC/DOR) in HIV positive patients.

  24 weeks

Secondary Outcomes (15)

• Percentage of patients with treatment-related adverse events by week 48

  48 weeks

• Median change in body fat content (g) measured by Total body dexa at week 24 and 48

  48 weeks

• Body composition changes when measured by waist circumference at week 24 and 48

  48 weeks

• Change in insulin sensitivity from baseline to week 24 and 48 by HOMA-IR (glucose & insulin levels)

  48 weeks

• PBMC cholesterol and cholesteryl levels

  48 weeks

Study Arms (2)

immediate switch arm

EXPERIMENTAL

Experimental arm (baseline visit switch group, N=30): One DOR/TDF/3TC tablet taken orally once daily for 48 weeks. Virally suppressed participants on a stable combined ART regimen will be randomised (1:1) to an immediate switch to 3TC/TDF/DOR (immediate switch arm, N=30) for the duration of the 48-week study, or to maintaining their current cART followed by a switch to 3TC/TDF/DOR from week 24-48 (delayed switch arm, N=30). Participants will be monitored for the length of the study (48 weeks) plus a 30-day follow-up period.

Drug: DELSTRIGO 100Mg-300Mg-300Mg Tablet

delayed switch arm

ACTIVE COMPARATOR

Control arm (deferred switch group, N=30): Participants will continue their current triple cART regimen for 24 weeks, and then switched to taking one TDF/3TC/DOR tablet orally once daily (24 -48 weeks). Virally suppressed participants on a stable combined ART regimen will be randomised (1:1) to an immediate switch to 3TC/TDF/DOR (immediate switch arm, N=30) for the duration of the 48-week study, or to maintaining their current cART followed by a switch to 3TC/TDF/DOR from week 24-48 (delayed switch arm, N=30). Participants will be monitored for the length of the study (48 weeks) plus a 30-day follow-up period.

Drug: DELSTRIGO 100Mg-300Mg-300Mg Tablet

Interventions

DELSTRIGO 100Mg-300Mg-300Mg Tablet DRUG

Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine \- TDF/3TC/DOR)

delayed switch arm; immediate switch arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• HIV-1 infected, 18 years or older
• On stable \& suppressive triple cART containing ABA/3TC or TAF/FTC plus dolutegravir or bictegravir for at least 6 months
• No evidence of resistance to TDF, 3TC, or DOR
• No laboratory abnormalities, medical/psychiatric conditions or alcohol/drug use considered a barrier to participation by investigators
• Women who are of childbearing potential and sexually active need to use the hormonal contraceptive methods, associated with inhibition of ovulation, listed in the protocol:
• Implant
• Depot injection
• Intra-uterine device or system
• Oral hormonal contraception A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
• Men who are sexually active and have partners who are women of childbearing potential must be using an adequate method of contraception to avoid pregnancy (male condom or sterilisation confirmed prior to the subject's entry into the study)

You may not qualify if:

• History of virological failure on an NNRTI in absence of a post-failure genotypic resistance test proving absence of resistance to DOR
• Concomitant medication contra-indicated with TDF, FTC or DOR
• Haemoglobin \<9 g/dL
• Platelets \<80,000/mm3
• Creatinine clearance \<50 mL/min
• AST or ALT ≥5N
• Acute Hepatitis A infection.
• Concomitant DAA for anti-HCV therapy
• Known acute or chronic viral hepatitis B or C.
• o Individuals with positive anti-HCV results, but with HCV RNA not detected may be included on the trial.
• Pregnant or breastfeeding women, or individuals actively trying to conceive
• History of osteoporosis or bone fractures/loss
• Hypersensitivity to the active substance or to any of the excipients in tenofovir disoproxil fumarate, lamivudine and/or doravirine formulations
• Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.

Sponsors & Collaborators

• Chelsea and Westminster NHS Foundation Trust: lead
• Merck Sharp & Dohme LLC: collaborator

Study Sites (2)

Chelsea and Westminster Hospital NHS Foundation Trust

London, London, SW10 9NH, United Kingdom

Location

Mortimer Market Centres

London, London, WC1E6JB, United Kingdom

Location

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

HIV Infections; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 26, 2022
• First Posted: March 22, 2022
• Study Start: November 21, 2023
• Primary Completion: November 21, 2024
• Study Completion: November 21, 2024
• Last Updated: December 10, 2024

Record last verified: 2024-12

Locations

GB (2)